Compare Oncolys BioPharma, Inc. with Similar Stocks
Dashboard
1
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -349.00
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -349.00
2
Poor long term growth as Operating profit has grown by an annual rate 1.24% of over the last 5 years
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
JPY 70,783 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.78
-46.15%
19.70
Revenue and Profits:
Net Sales:
500 Million
(Quarterly Results - Jun 2026)
Net Profit:
-348 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
136.8%
0%
136.8%
6 Months
151.2%
0%
151.2%
1 Year
916.18%
0%
916.18%
2 Years
999.82%
0%
999.82%
3 Years
990.28%
0%
990.28%
4 Years
1151.0%
0%
1151.0%
5 Years
417.3%
0%
417.3%
Oncolys BioPharma, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-36.50%
EBIT Growth (5y)
1.24%
EBIT to Interest (avg)
-352.14
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.76
Sales to Capital Employed (avg)
0.01
Tax Ratio
0.26%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
20.75
EV to EBIT
-43.23
EV to EBITDA
-43.23
EV to Capital Employed
92.71
EV to Sales
2267.57
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-214.48%
ROE (Latest)
-46.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Bullish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
500.00
3.10
16,029.03%
Operating Profit (PBDIT) excl Other Income
-346.80
-420.70
17.57%
Interest
5.90
3.00
96.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-347.70
-414.50
16.12%
Operating Profit Margin (Excl OI)
-693.80%
-136,155.70%
13,546.19%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 16,029.03% vs 0.00% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 16.12% vs 6.01% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
28.50
31.40
-9.24%
Operating Profit (PBDIT) excl Other Income
-2,023.80
-1,680.60
-20.42%
Interest
5.20
4.60
13.04%
Exceptional Items
-2.80
-17.10
83.63%
Consolidate Net Profit
-2,058.00
-1,684.80
-22.15%
Operating Profit Margin (Excl OI)
-70,905.50%
-53,575.20%
-1,733.03%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -9.24% vs -50.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -22.15% vs 13.09% in Dec 2024
About Oncolys BioPharma, Inc. 
Oncolys BioPharma, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






